Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
about
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agentPixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasA comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Emerging DNA topisomerase inhibitors as anticancer drugs.The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for hTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.Pixantrone: merging safety with efficacy.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
P2860
Q24671854-057B2A0E-7E32-4D20-90DE-F3209295DC3CQ33376932-C227739B-6CA8-401E-8A83-9D52E7F8A487Q33728214-B76A0168-894F-4244-9AA4-BB9A7834EE18Q35753383-4ECB20FE-FAB5-45D1-B2ED-160863E7904FQ35779294-65904F59-ED34-489E-8481-91D41BE3ED36Q36871726-A7BA665B-E98E-4CA3-AD1A-D973BE4F97D6Q37178611-7F45FB4E-41F6-4461-8DA5-FC840614A178Q37486763-8CDD1B34-B8E5-4423-81D1-A5ACCF49A73FQ37633429-B45815FD-492D-4D60-998C-D4A8351DDE63Q37766891-F0A2B8BA-7C63-4B72-86A3-83E6E4A382AEQ37929798-70C25E83-DB18-4E15-A9DD-9A2739D74761Q38078425-5544E38A-4308-4E23-8154-3D1EA136404CQ38190105-A9DD4DA0-AB9C-471B-99A6-7F55A2DAFC30Q38819940-92AEE1BC-85B2-4AF0-B3D4-1EF72DCFC133Q38984987-7BBF034D-75C1-4093-8514-9C9B975CFDF7Q43412243-FCA32840-4CC0-414D-A6BA-5A3048BFF985Q44950915-E13D203C-37F9-47F5-8B8D-A95CC70A5FD9
P2860
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@en
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@nl
type
label
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@en
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@nl
prefLabel
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@en
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@nl
P2093
P356
P1433
P1476
Phase I study of BBR 2778, a n ...... actory non-Hodgkin's lymphoma.
@en
P2093
A Bernareggi
G M Camboni
P Borchmann
R Knippertz
P304
P356
10.1023/A:1011139016294
P577
2001-05-01T00:00:00Z